New heart transplant drug combo aims to spare kidneys
NCT ID NCT06478017
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether a drug called belatacept, combined with a gradual reduction of tacrolimus, can safely prevent organ rejection in heart transplant recipients while protecting kidney function. About 66 adults who receive a new heart will be randomly assigned to either standard care or the belatacept-based regimen. The study will track rejection episodes, kidney health, and survival over 18 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
belatacept (NULOJIX)
What this could lead to
If successful, this could offer heart transplant patients a safer immunosuppression option that reduces long-term kidney damage.
What could go wrong
This is a small, early-phase trial (66 people) testing safety and rejection rates. The belatacept regimen may not prevent rejection as well as standard care, and patients still need lifelong medication.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART TRANSPLANT are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cedars Sinai Heart Institute/ Cedars Sinai Medical (Site # 71146)
RECRUITINGLos Angeles, California, 90048, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
NYU Langone Health (Site # 71177)
RECRUITINGNew York, New York, 10016, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
St. Luke's Hospital of Kansas City
RECRUITINGKansas City, Missouri, 64111, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tampa General Hospital (Site # 71150)
RECRUITINGTampa, Florida, 33606, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Utah Medical Center (Site # 71126)
RECRUITINGSalt Lake City, Utah, 84132, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••